# 2026-08524: FDA Wants Your Take on Patient Drug Meeting Impacts

2026-08524, Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-01, effective 2026-06-30; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08524
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08524
- Title: Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 23426
- Published: 2026-05-01
- Effective: 2026-06-30
- Comments close: 2026-06-30
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Wants Your Take on Patient Drug Meeting Impacts

## Summary

The FDA wants to hear from patients, advocates, and drug developers about how past patient-focused drug meetings have helped shape medicine and research. They’ve opened a public comment period until June 30, 2026, to collect stories and ideas that could improve future drug development. This is a great chance for anyone involved in healthcare to share their experience and influence how new treatments are made—no cost to participate, just your voice!

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect examples about how previous patient-focused drug development (PFDD) meetings have impacted stakeholders' drug development efforts. This includes impacts on community engagement, research priorities, advocacy strategies, medical product development programs, clinical practice, and other areas of interest.

## Effects PRIA read

- FDA opens PFDD public docket: benefit, low. The FDA has created a public docket (Docket No. FDA-2026-N-3947) to collect examples of how past patient-focused drug development (PFDD) meetings affected community engagement, research priorities, advocacy strategies, medical product development programs, and clinical practice. Patients, caregiver…
- Comment deadline and confidentiality rules: mixed, low. Comments must be submitted by June 30, 2026 (electronic submissions accepted via https://www.regulations.gov until 11:59 p.m. Eastern Time that day, or written/paper submissions received by that date at Dockets Management Staff, FDA, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852). Comments poste…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08524 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/01/2026-08524/impacts-of-patient-focused-drug-development-meetings-establishment-of-a-public-docket-request-for)
- [2026-08524 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08524.pdf)

## Related
- [Previous: 2026-08523, Formations of, Acquisitions by, and Mergers of Bank Holding Companies](https://policyrisk.com/federal-register/2026-08523)
- [Next: 2026-08525, Agency Information Collection Extension](https://policyrisk.com/federal-register/2026-08525)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08524 (as of 2026-06-08).
